GeneOne Life Science and Inovio Pharmaceuticals’ MERS Vaccine Approved for First-in-Human Study
November 19 2015 - 9:00AM
GeneOne Life Science Inc. (KSE:011000) today announced that the
U.S. Food and Drug Administration has cleared the first-in-human
clinical study of its collaborative vaccine for MERS (Middle East
Respiratory Syndrome). GeneOne Life Science and Inovio
Pharmaceuticals (NASDAQ:INO) are co-developing the vaccine and plan
to initiate the first human trial of a MERS vaccine before the end
of the year in partnership with the Walter Reed Army Institute of
Research (WRAIR).
Earlier this month, GeneOne Life Science signed a joint clinical
development agreement with WRAIR to advance the MERS vaccine. As
part of this agreement, the relevant MERS vaccine clinical trial
will be conducted at Walter Reed Army Institute of Research.
Middle East Respiratory Syndrome is caused by a coronavirus that
is related to the severe acute respiratory syndrome (SARS) virus
that over 10 years ago infected more than 8,000 people, with a 10%
death rate. There is no vaccine or effective treatment against
MERS, which spreads from human to human. Since 2012, MERS has
infected over 1,500 people and killed almost 600 (40%). Recently,
the largest outbreak outside of Saudi Arabia of this emergent
global health concern infected 186 people with 36 fatalities in
South Korea.
Mr. Young K. Park, CEO, GeneOne Life Science, said, “We are
moving rapidly with our partners to bring a MERS vaccine to
medicine because there is no vaccine or treatment for this virulent
virus that has triggered widespread outbreaks and deaths in the
Middle East and more recently Korea.
About GeneOne Life Science
GeneOne Life Science Inc. is an international DNA vaccine
developer and leading contract manufacturer of DNA plasmid-based
agents for pre-clinical and clinical trials for global companies
and institutions. It researches and develops DNA vaccines to
prevent and treat incurable diseases in South Korea and
internationally. The company is headquartered in Seoul, South
Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary
located in Texas, is the largest pure-play cGMP DNA plasmid
manufacturing facility in the world.
GeneOne Life Science
Jeffrey C. Richardson
267-440-4211
jeff@richardsonglobalpr.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024